Journal
CANCER SCIENCE
Volume 114, Issue 5, Pages 1783-1791Publisher
WILEY
DOI: 10.1111/cas.15731
Keywords
biomarker; cancer; glycoproteomics; mass spectrometry; proteogenomics
Categories
Ask authors/readers for more resources
Proteomic analysis has become an important tool in understanding the molecular characteristics of cancer. The use of mass spectrometry allows for direct examination of protein variants and modifications. Integrating proteomic data with genomic, epigenomic, and transcriptomic data has led to new knowledge in the field of proteogenomics. Deep proteomic profiling has potential clinical applications in cancer research and personalized medicine.
Numerous omics studies, primarily genomics analyses, have been conducted to fully understand the molecular biological characteristics of cancer. In recent years, the depth of proteomic analysis, which comprehensively analyzes proteins and molecules that function directly in vivo, has increased dramatically. Proteomics using mass spectrometry (MS) is a promising technology to directly examine proteoforms, including post-translational modifications and variants originating from genomic aberrations. Recent advances in MS-based proteomics have enabled direct, in depth, and quantitative analysis of the expression levels of various cancer-related proteins, as well as their cancer-specific proteoforms, and proteins that fluctuate with cancer initiation and progression in cell lines and tissue samples. Additionally, the integration of proteomic data with genomic, epigenomic, and transcriptomic data has formed the growing field of proteogenomics, which is already yielding new biological and diagnostic knowledge. Deep proteomic profiling provides clinically useful information in various aspects, including understanding the mechanisms of cancer development and progression and discovering targets for diagnosis and drug development. Furthermore, it is expected to make a significant contribution to the promotion of personalized medicine. In this review, recent advances and impacts in MS-based clinical proteomics are highlighted with a focus on oncology.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available